Literature DB >> 15012593

Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.

A Acitores1, N González, V Sancho, I Valverde, M L Villanueva-Peñacarrillo.   

Abstract

Glucagon-like peptide-1 (GLP-1), an incretin with glucose-dependent insulinotropic and insulin-independent antidiabetic properties, has insulin-like effects on glucose metabolism in extrapancreatic tissues participating in overall glucose homeostasis. These effects are exerted through specific receptors not associated with cAMP, an inositol phosphoglycan being a possible second messenger. In rat hepatocytes, activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB), protein kinase C (PKC) and protein phosphatase 1 (PP-1) has been shown to be involved in the GLP-1-induced stimulation of glycogen synthase. We have investigated the role of enzymes known or suggested to mediate the actions of insulin in the GLP-1-induced increase in glycogen synthase a activity in rat skeletal muscle strips. We first explored the effect of GLP-1, compared with that of insulin, on the activation of PI3K, PKB, p70s6 kinase (p70s6k) and p44/42 mitogen-activated protein kinases (MAPKs) and the action of specific inhibitors of these kinases on the insulin- and GLP-1-induced increment in glycogen synthase a activity. The study showed that GLP-1, like insulin, activated PI3K/PKB, p70s6k and p44/42. Wortmannin (a PI3K inhibitor) reduced the stimulatory action of insulin on glycogen synthase a activity and blocked that of GLP-1, rapamycin (a 70s6k inhibitor) did not affect the action of GLP-1 but abolished that of insulin, PD98059 (MAPK inhibitor) was ineffective on insulin but blocked the action of GLP-1, okadaic acid (a PP-2A inhibitor) and tumour necrosis factor-alpha (a PP-1 inhibitor) were both ineffective on GLP-1 but abolished the action of insulin, and Ro 31-8220 (an inhibitor of some PKC isoforms) reduced the effect of GLP-1 while completely preventing that of insulin. It was concluded that activation of PI3K/PKB and MAPKs is required for the GLP-1-induced increment in glycogen synthase a activity, while PKC, although apparently participating, does not seem to play an essential role; unlike in insulin signaling, p70s6k, PP-1 and PP-2A do not seem to be needed in the action of GLP-1 upon glycogen synthase a activity in rat muscle.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012593     DOI: 10.1677/joe.0.1800389

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  11 in total

1.  Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Authors:  Nitika Arora Gupta; Jamie Mells; Richard M Dunham; Arash Grakoui; Jeffrey Handy; Neeraj Kumar Saxena; Frank A Anania
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

2.  Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

Authors:  Dominique Dardevet; Mary Courtney Moore; Catherine A DiCostanzo; Ben Farmer; Doss W Neal; Wanda Snead; Margaret Lautz; Alan D Cherrington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-28       Impact factor: 4.052

3.  Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.

Authors:  Siva Bhashyam; Anjali V Fields; Brandy Patterson; Jeffrey M Testani; Li Chen; You-Tang Shen; Richard P Shannon
Journal:  Circ Heart Fail       Date:  2010-05-13       Impact factor: 8.790

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes.

Authors:  Hong Gao; Xinjun Wang; Zhiguo Zhang; Yisheng Yang; Jun Yang; Xiaoying Li; Guang Ning
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

6.  The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.

Authors:  Nitika A Gupta; Vasantha L Kolachala; Rong Jiang; Carlos Abramowsky; Rene Romero; Nimita Fifadara; Frank Anania; Stuart Knechtle; Allan Kirk
Journal:  Am J Pathol       Date:  2012-09-05       Impact factor: 4.307

7.  Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats.

Authors:  Susan E Swithers; Alycia F Laboy; Kiely Clark; Stephanie Cooper; T L Davidson
Journal:  Behav Brain Res       Date:  2012-04-26       Impact factor: 3.332

8.  Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway.

Authors:  Jian-Hui Liu; Fei Yin; Li-Xia Guo; Xiao-Hong Deng; Yin-He Hu
Journal:  Acta Pharmacol Sin       Date:  2009-01-19       Impact factor: 6.150

9.  Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment.

Authors:  Zhenhua Dong; Weidong Chai; Wenhui Wang; Lina Zhao; Zhuo Fu; Wenhong Cao; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-11-27       Impact factor: 4.310

10.  Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia.

Authors:  Charlotte J Green; Tora I Henriksen; Bente K Pedersen; Thomas P J Solomon
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.